This webcast featuring a dialogue and case studies with a retinal specialist and an optometrist and will review disease prevalence, advanced diagnostic imaging, pivotal treatment trials, and challenging case studies.
This certified COPE activity is designed for optometrists involved in the management of patients with diabetes.
Supported through an independent medical education grant from Genentech.
This initiative is designed to address and resolve the educational needs through the following educational objectives:
• Describe the increasing prevalence of diabetes and diabetic retinopathy.
• Identify and implement screening guidelines for patients based on their risk factors.
• Explain to patients the need for early referral to a retina specialist.
• Understand advances in imaging and how these allow for earlier diagnosis of disease or disease progression.
• Identify the novel therapies under investigation for the treatment of DR and DME.
Credit Designation Statement
Evolve Medical Education LLC (Evolve) is an approved COPE administrator.
This course is COPE approved for 1.0 hours of CE Credit for Optometrists.
Please proceed through the program, complete the post-test, evaluation and submit for credit.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
Dilsher S. Dhoot, MD
California Retina Consultants
Steven G. Ferrucci, OD, FAAO
Optometry Department, Sepulveda VA Medical Center
Southern California College of Optometry
The following faculty have the following financial relationships with commercial interests:
Dilsher Dhoot, MD, and or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Alimera Sciences, Bayer, Eyepoint Pharmaceuticals, Genentech, Novartis, Santen, and Regeneron Pharmaceuticals; Grant/Research: Genentech, Regeneron Pharmaceuticals; Speakers Bureau: Alimera Sciences, Eyepoint Pharmaceuticals, Genentech, Novartis, and Regeneron Pharmaceuticals; Stocks: Vortex Surgical.
Editorial Support Disclosures:
The staff and planners involved in this activity have no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Genentech Pharmaceuticals.